期刊文献+

Oct-4基因在胃癌顺铂耐药中的作用 被引量:3

Effect of Oct-4 on chemosensitivity of cisplatin against gastric cancer cells
下载PDF
导出
摘要 目的:建立胃癌BGC-823顺铂耐药细胞株,研究Oct-4基因在胃癌顺铂耐药中的作用。方法:使用顺铂逐步增加剂量法诱导胃癌BGC-823细胞,以建立其多药耐药细胞株BGC-823/DDP;MTT细胞毒实验检测顺铂对肿瘤细胞的细胞毒作用;半定量RT-PCR检测Oct-4基因的表达;基因转染干扰Oct-4表达;Western blot实验检测Oct-4蛋白的表达改变。结果:经过30~34周的诱导我们建立了胃癌BGC-823顺铂耐药细胞株;MTT细胞毒实验结果显示顺铂对BGC-823和BGC-823/DDP细胞的IC50值分别为(2.33±0.12)和(21.46±0.97)μmol/L(P<0.01),与BGC-823细胞比较,BGC-823/DDP细胞对顺铂耐药是其9.21倍;半定量RT-PCR检测显示胃癌耐药株BGC-823/DDP高表达Oct-4基因;Western blot结果显示化学合成的siRNA可以靶向下调Oct-4蛋白的表达;siRNA干扰BGC-823/DDP细胞Oct-4基因的表达后,BGC-823/DDP细胞对顺铂的的IC50值从(22.04±1.84)μmol/L减小到(6.15±0.53)μmol/L,二者差异具有统计学意义(P<0.01)。结论:研究结果表明,Oct-4基因的高表达在胃癌顺铂的耐药中起着重要的作用。 To explore the mechanisms of multidrug resistance in human gastric cancer by establishing a eisplatin (DDP) resistance BGC-823 cell line. METHODS: The human cancer BGC-823 cells were exposed in a gradual- ly increasing dose of DDP. MTT assay was used to detect the eytotoxic activity of DDP against BGC-823 and BGC-823/DDP cells. The mRNA expression of Oct-4 was detected by RT-PCR a- nalysis. The small interfering RNA was used tospecifically knockdown Oct-4 in BGC-823/DDP cells. The protein expression of Oct-4 was deter- mined by Western blot analysis. RESULTS.DDP resistance cell line BGC-823/DDP was estab- lished by DDP 30-34 weeks contionuous indu- cing. The ICs0 values of DDP against BGC-823 and BGC-823/DDP cells were (2.331- 0.12) and (21.46±0.97) μmol/L by MTT assay, respec- tively. Compared with the BGC-823 cells, the re- sistance to cisplatin of BGC-823/DDP cells was 9.21 times. Semi-quantitative RT-PCR analysisshowed that the mRNA expression of Oct-4 was upregulated in BGC-823/DDP cells. Western blot showed that the expression of Oct-4 protein was down-regulated by the chemical synthesis siR- NA;After interfered the Oct-4 gene expression of BGC-823/DDP cells by siRNA,the ICs0 values of cisplatin against BGC-823/DDP cells was de- creased from (22.04±1.84) to (6.15±0.53)/2mol/L;there was no significant difference (P〈 0.01). CONCLUSION: The results show that Oct-4 gene expression plays an important role in gastric cancer with cisplatin resistance. KEY WORDS Gastric cancer; BGC-823 cell; Multidrug resistance; Oct-4 gene
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第3期251-255,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 胃癌 BGC-823细胞 多药耐药 OCT-4 基因 Gastric cancer BGC-823 cell Multidrug resistance Oct-4 gene
  • 相关文献

参考文献4

二级参考文献74

  • 1蔡鹏,刘叙仪,韩复生,王萍.耐顺铂人肺腺癌细胞系A_(549)DDP的建立及耐药机制[J].中国肿瘤临床,1995,22(8):582-587. 被引量:29
  • 2李羲,郭先健,钱桂生,黄桂君.人肺腺癌多药抗药细胞系LC-3/CDDP细胞周期及DNA含量变化[J].河南肿瘤学杂志,1997,10(2):93-93. 被引量:4
  • 3Jensen OM, Parkin DM, Maclennan R, et al. Cancer registration: principles and methods, IARC scientific publication No. 95[M]. Lyon: IARC, 1991.
  • 4Parkin DM, Chen VW, Ferlay J, et ah Comparability and quality control in Cancer Registration. IARC technical report No.19[M]. Lyon: IARC, 1994.
  • 5Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 6Felay J. The IARCcrgTools program[DB/OL], http://www.i- acr.com.fr/iarccrgtools.htm, 2006.
  • 7中国人民共和国卫生部.第三次全国死因调查主要情况[R].北京:卫生部新闻发布会,2008.
  • 8Zamble DB, Llppard SJ. Cisplatin and DNA repair in cancer chemotherapy[J]. Trends Biochem Sci, 1995, 20(10) :435--439.
  • 9Ahaha R, Llang X, Yu J J, et al. Excision repair cross complementing group 1 : gene expression and platinum resistance[J]. Int J Mol Med, 2004, 14 (6) : 959--970.
  • 10Bermstein C, Bernstein H, Payne CM, et al. DNA repair/proapoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis[J]. Mutr Res, 2002,5 (11):145 -- 178.

共引文献56

同被引文献33

  • 1王敏,孙颖,孙凤娟,王欣彦,高山,张淑兰.卵巢癌、宫颈癌及子宫内膜癌组织中环氧合酶-2的表达及临床意义[J].中国现代医学杂志,2006,16(13):1961-1964. 被引量:6
  • 2Siegel R,Naishadham D,Jemal A. Cancer statis-tics, 2012[J].CA Cancer J Clin, 2012, 62(1): 10 —29.
  • 3Shah MA, Power DG, Kindler HL et al. A multi-center, phase II study of bortezomib (PS-341) inpatients with unresectable or metastatic gastric andgastroesophageal junction adenocarcinoma [ J ]. In-vest New Drugs, 2011, 29(6) : 1475 —1481.
  • 4Weber DM, Graef T, Hussein M,et al. Phase Itrial of vorinostat combined with bortezomib for thetreatment of relapsing and/or refractory multiplemyeloma [J]. Clin Lymphoma Myeloma Leuk,2012, 12(5):319—324.
  • 5Li W,Li Y, Tan Y,et al. Bmi-1 is critical for theproliferation and invasiveness of gastric carcinomacells[J]. J Gastroenterol Hepatol, 2010,25(3):568-575.
  • 6Jon'lan CT, Guzman ML, Noble M. Cancer stem cells [ J ]. N Engl J Med ,2006,355 ( 12 ) : 1253 - 1261.
  • 7Ma W,Ma J,Xu J,et al. Lin28 regulates BMP4 and functions with OCT4 to 'affect ovarian tumor microenvironment [ J ]. Cell Cycle, 2013,12(1) :88 -97.
  • 8Kato K. Endometrial cancer stem cells:a new target for cancer ther- apy [ J ]. Anticancer Res ,2012,32 (6) :2283 - 2293.
  • 9Takaishi S, Okaumura T,Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CIM4 [ J ]. Stem Ceils, 2009,27 ( 5 ) : 1006 - 1020.
  • 10Schoeftner S, Scarola M, Comisso E, et al. An OCT4 - pRb axis, controlled by MiR - 335, integrates stem cell see - renewal and cell cyclecontrol [ J ]. Stem Cells, 2012,31 ( 4 ) :717 - 728.

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部